MEVLYQ

This brand name is authorized in Estonia, Croatia, Ireland, Italy, Lithuania

Active ingredients

The drug MEVLYQ contains one active pharmaceutical ingredient (API):

1 Eribulin mesylate
UNII AV9U0660CW - ERIBULIN MESYLATE

Eribulin is a microtubule dynamics inhibitor belonging to the halichondrin class of antineoplastic agents. It is a structurally simplified synthetic analogue of halichondrin B, a natural product isolated from the marine sponge Halichondria okadai.

Read about Eribulin mesylate

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
MEVLYQ Solution for injection European Medicines Agency (EU) MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
L01XX41 Eribulin L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XX Other antineoplastic agents
Discover more medicines within L01XX41

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: EE Ravimiamet Identifier(s): 3064878
Country: IT Agenzia del Farmaco Identifier(s): 051108013
Country: LT Valstybinฤ— vaistลณ kontrolฤ—s tarnyba Identifier(s): 1099022

ยฉ All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈